Evidence map›Paper›PMID 33352786›Full record

ReviewVaccines2020

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease.

Joan G Tell, Beth-Ann G Coller, Sheri A Dubey, Ursula Jenal, William Lapps, Liman Wang, Jayanthi Wolf

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Harnessing Nanocarriers to Advance Vaccine Development.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Joan G TellMerck & Co., Inc., Kenilworth, NJ 07033, USA.ORCID 0000-0003-0558-1986
Beth-Ann G CollerMerck & Co., Inc., Kenilworth, NJ 07033, USA.
Sheri A DubeyMerck & Co., Inc., Kenilworth, NJ 07033, USA.
Ursula JenalJenal & Partners Biosafety Consulting, 4310 Rheinfelden, Switzerland.
William LappsMerck & Co., Inc., Kenilworth, NJ 07033, USA.
Liman WangMerck & Co., Inc., Kenilworth, NJ 07033, USA.
Jayanthi WolfMerck & Co., Inc., Kenilworth, NJ 07033, USA.ORCID 0000-0002-2837-8262
Merck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

Merck n/a
6 · The paper itself

Abstract

rVSVΔG-ZEBOV-GP is a live, attenuated, recombinant vesicular stomatitis virus (rVSV)-based vaccine for the prevention of Ebola virus disease caused by

Indexed as

environmental impactERAERVEBO®GMOrecombinant vaccinerVSVsheddingvesicular stomatitis virusviremiaZaire ebolavirus

Identifiers

PMID33352786
PMCPMC7767225
OpenAlexW3114935186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.